Physician profile
James D Mitchell
NPI 1700057569
$63,516.61
in general payments reported to CMS, 2019-2025
35 companies · $62K in 2025
The $62K reported for 2025 was more than what 99% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.11 · 2021: $79.32 · 2022: $34.71 · 2023: $312 · 2024: $1,005 · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $60K · Food and Beverage: $2,252 · Travel and Lodging: $1,006 · Education: $96.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $60,000.00 |
| Food and Beverage | $2,252.11 |
| Travel and Lodging | $1,006.36 |
| Education | $96.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pavmed INC. | $60,000.00 | 2025 | |
| Elekta, INC. | $1,182.17 | 2025 | Elekta Medical Linear Accelerator, Elekta Unity |
| Novocure INC. | $246.97 | 2022-2025 | Optune |
| Abbvie INC. | $196.83 | 2024-2025 | |
| Icotec Medical INC. | $172.11 | 2025 | Kong-Tl Vbr, End Plate, Round, L and Screw, 12 X 43 Mm, Kong-Tl Vbr E, Expandable Body, L, 19 Mm X 27 - 37 Mm, Kong-Tl Vbr, End Plate, Rectangular, M and Screw, 12 X 33 Mm |
| Telix Pharmaceuticals | $165.23 | 2023-2024 | Illuccix |
| Astrazeneca Pharmaceuticals LP | $156.03 | 2024-2025 | Imfinzi, Enhertu, Tagrisso |
| Exelixis INC. | $118.01 | 2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $112.13 | 2024-2025 | Keytruda |
| Novartis Pharmaceuticals Corporation | $108.84 | 2023-2024 | |
| Coherus Oncology, INC. | $87.72 | 2024 | |
| Pfizer INC. | $79.13 | 2024 | |
| Pharmaessentia USA Corporation | $74.81 | 2024-2025 | Besremi |
| Janssen Biotech, INC. | $71.84 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Genzyme Corporation | $71.60 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $68.44 | 2023-2024 | Prolaris, Precisetumor |
| Zap Surgical Systems, INC. | $56.23 | 2023 | Zap-X Radiosurgery System, Zap-X Treatment Planning Software, Zap-X Mv Imager |
| Genentech USA, INC. | $52.22 | 2025 | Venclexta, Polivy |
| Lilly USA, LLC | $46.67 | 2024 | Verzenio, Jaypirca |
| Spectrum Pharmaceuticals INC. | $44.03 | 2024-2025 | Rolvedon |
| Gilead Sciences, INC. | $43.60 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.59 | 2022-2024 | |
| Agios Pharmaceuticals, INC. | $37.87 | 2024 | |
| Genmab U.S., INC. | $32.58 | 2024 | Epkinly |
| Amgen INC. | $30.72 | 2021 | |
| Puma Biotechnology, INC. | $27.34 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $26.98 | 2021 | |
| Aveo Pharmaceuticals, INC. | $26.17 | 2025 | |
| Servier Pharmaceuticals LLC | $22.75 | 2025 | |
| Argenx US, INC. | $21.77 | 2024 | Vyvgart Hytrulo |
| Seagen INC. | $21.62 | 2021 | |
| Varian Medical Systems, INC. | $19.67 | 2019 | |
| Eisai INC. | $19.62 | 2024 | |
| Hologic Sales and Service, LLC | $16.72 | 2023 | Trident Specimen Radiography System |
| Karyopharm Therapeutics INC. | $16.60 | 2025 | Xpovio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.